Quiver Quantitative
BREAKING: The House is currently holding a hearing on congressional stock trading.

"In recent years, social media accounts have generated significant media attention for aggregating the stock trades of members of Congress"

- @RepBryanSteil https://t.co/g5NijR7wcm
tweet

Wasteland Capital
$GOOG +104%, All Time High at $304, +60% YTD.

One of the most over-analysed stocks in the world. Yet someone was first to claim it wasn’t DEAD last September. Many followed. No data supported the “it’s dead” narrative, and hasn’t since.

Trust the numbers. Trust looking ahead.

$GOOG now +40% after I bottom-ticked it on the hour in September. Many followed. Remember the fear then? “Google is about to die - again” LOL.

The fact you can make 40%+ on GOOGLE in 4+ months in the public markets is just f **king insane. Crazy mispricing. Easiest gain ever. https://t.co/OOtM2JYH3q - Wasteland Capital
tweet

Quiver Quantitative
Wow.

Republican Bryan Steil just called out suspicious stock trades by former Republican Senator Richard Burr. https://t.co/szHOgCWg8p
tweet

EndGame Macro
If you’re not already following David Levenson @levenson_david, you should be.
He’s one of the few people who can look across different markets and actually connect what’s really going on. 💪 https://t.co/7OHRrjfVnv
tweet

Fiscal.ai
RT @StockMKTNewz: Heading into today's earnings Nvidia's $NVDA data center business is currently a

$164.4 Billion run rate segment https://t.co/oFJ3dBUXM8
tweet

Quiver Quantitative
Representative Tim Burchett on proposals to ban congressional trading:

“Let’s give America a reason to trust Congress for once in our miserable lives”

https://t.co/YpFoavz5xv
tweet

Quiver Quantitative
BREAKING: Representative Greg Murphy just called out stock trades by Pelosi.

Full trade list up on Quiver. https://t.co/BJUNmrMGp1
tweet

WealthyReadings
$TMDX is one of the most interesting growth names in the med-tech sector, and one of the most interesting stocks in the entire market right now.

Here’s why 👇

🔷 The only company providing an end-to-end transplant system in the U.S., from organ recovery to transportation to transplant surgery.
🔷 Leader in organ-preservation technology with growing demand and innovative solutions.
🔷 Rising adoption of their technologies and services.
🔷 Upgrading both lung and heart platforms in FY26, with expansion into kidneys by 2028.
🔷 International expansion coming in Europe in 2026 and more regions after.
🔷 Hospitals tend to rely on specific technologies for decades once integrated into their workflow.
🔷 Revenue growth has been consistent, with multiple levers to sustain it for years.
🔷 Margins are expanding.
🔷 Valuation remains well below comparable med-tech innovators.

The bear case?
🔷 Regulations and social security systems can slow progress - innovation & expansion.
🔷 Reputation is critical in this sector and can be impacted by internal or external events.

You'll find more details in the full breakdown below, but one conclusion stands: $TMDX is one of the most innovative and transformative companies in med-tech, offering a service and product no one else does.

Question is, how long before the market finally prices in the growth story and the importance of their service and hardware in the future of transplants?
tweet

Quiver Quantitative
BREAKING: Representative Norma Torres just implied that Attorney General Pam Bondi made stock trades based off inside information. https://t.co/9iZtApXwB1
tweet

WealthyReadings
🔥Hot take: $DUOL is the next $NFLX.

Yet, you shouldn't buy it right now.

I don't. And I explain you why 👇
https://t.co/IqtMqADQqt
tweet